Untargeted metabolomics based on ultra-high performance liquid chromatography-mass spectrometry/MS reveals the lipid-lowering mechanism of taurine in hyperlipidemia mice

Xinzhe Guo, Tong Ou, Xinyu Yang, Qi Song, Lin Zhu, Shengquan Mi, Jing Zhang, Yanzhen Zhang, Wen Chen, Junxia GuoFrontiers in Nutrition 2024 · DOI

Abstract

Introduction: Taurine has a prominent lipid-lowering effect on hyperlipidemia. However, a comprehensive analysis of the effects of taurine on endogenous metabolites in hyperlipidemia has not been documented. This study aimed to explore the impact of taurine on multiple metabolites associated with hyperlipidemia.

Methods: The hyperlipidemic mouse model was induced by high-fat diet (HFD). Taurine was administered via oral gavage at doses of 700 mg/kg/day for 14 weeks. Evaluation of body weight, serum lipid levels, and histopathology of the liver and adipose tissue was performed to confirm the lipid-lowering effect of taurine. Ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS)-based metabonomics analyses of serum, urine, feces, and liver, coupled with multivariate data analysis, were conducted to assess changes in the endogenous metabolites.

Results and discussion: Biochemical and histological examinations demonstrated that taurine administration prevented weight gain and dyslipidemia, and alleviated lipid deposition in the liver and adipose tissue in hyperlipidemic mice. A total of 76 differential metabolites were identified, mainly involving bile acids, glycerophospholipids, sphingomyelins, diglycerides, triglycerides, polyunsaturated fatty acids, and amino acids. Taurine effectively alleviates metabolic abnormalities caused by HFD, including fatty acid metabolism, sphingolipid metabolism, and bile acid metabolism. This study provides new evidence for taurine to prevent hyperlipidemia.

Introduction

Hyperlipidemia is a primary driver of cardiovascular disease and type 2 diabetes. While pharmacological interventions like statins are effective, they often come with significant side effects. Taurine, a conditionally essential amino acid found abundantly in seafood, has long been recognized for its lipid-lowering properties. However, the exact metabolic mechanisms have remained unclear. This study seeks to fill that gap by performing a comprehensive, multi-organ metabolomic analysis to see how taurine reshapes the metabolic landscape in hyperlipidemic mice.

Methods

The researchers employed a C57BL/6J mouse model, inducing hyperlipidemia via a high-fat diet (HFD) over 14 weeks. One group received a daily oral dose of 700 mg/kg of taurine. The core of the study is an untargeted metabolomics approach using Ultra-High Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) to analyze serum, liver, urine, and feces. To identify the detected molecules, the authors compared their MS/MS spectra against established biochemical databases like HMDB, METLIN, and KEGG.

Results

Physiological Impact and Histopathology

Taurine significantly prevented weight gain and improved serum lipid profiles. It lowered total cholesterol (TC), triglycerides (TG), and LDL-C, while preventing the drop in "good" HDL-C. Histopathological analysis of liver and adipose tissue showed a dramatic reduction in lipid droplets and vacuoles in the taurine-treated group compared to the HFD-only group.

Figure 1: Taurine prevented dyslipidemia and alleviated lipid accumulation in hyperlipidemic mice. Panels show (A) body weight, (B-E) serum lipid levels, and (F) histopathology of liver and fat tissue.

Metabolic Insights

The team identified 76 differential metabolites across the four sample types. Key findings include:

  • Lipotoxicity Reduction: Taurine reduced Diglycerides (DGs) in the liver, which are known to interfere with insulin signaling.
  • Bile Acid Excretion: Taurine accelerates the conversion of cholesterol into bile acids and increases their fecal excretion, facilitating cholesterol breakdown.
  • Restoring Beneficial Fats: Taurine supplementation helped restore levels of beneficial Polyunsaturated Fatty Acids (PUFAs) like DHA.

Discussion and Conclusion

Taurine acts as a metabolic "switch," shifting the body from fat synthesis to fat breakdown. By lowering lipotoxic DGs and restoring amino acid and lipid homeostasis, taurine provides a multi-layered defense against hyperlipidemia. While these results are promising, clinical trials are needed to confirm these mechanisms in humans, as metabolic rates differ significantly between species. This study provides a high-resolution map of metabolic changes, identifying potential biomarkers and therapeutic targets for future hyperlipidemia research.

Summary updated

Abstract

Introduction Taurine has a prominent lipid-lowering effect on hyperlipidemia. However, a comprehensive analysis of the effects of taurine on endogenous metabolites in hyperlipidemia has not been documented. This study aimed to explore the impact of taurine on multiple metabolites associated with hyperlipidemia. Methods The hyperlipidemic mouse model was induced by high-fat diet (HFD). Taurine was administered via oral gavage at doses of 700 mg/kg/day for 14 weeks. Evaluation of body weight, serum lipid levels, and histopathology of the liver and adipose tissue was performed to confirm the lipid-lowering effect of taurine. Ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS)-based metabonomics analyses of serum, urine, feces, and liver, coupled with multivariate data analysis, were conducted to assess changes in the endogenous metabolites. Results and discussion Biochemical and histological examinations demonstrated that taurine administration prevented weight gain and dyslipidemia, and alleviated lipid deposition in the liver and adipose tissue in hyperlipidemic mice. A total of 76 differential metabolites were identified by UPLC-MS-based metabolomics approach, mainly involving BAs, GPs, SMs, DGs, TGs, PUFAs and amino acids. Taurine was found to partially prevent HFDinduced abnormalities in the aforementioned metabolites. Using KEGG database and MetaboAnalyst software, it was determined that taurine effectively alleviates metabolic abnormalities caused by HFD, including fatty acid metabolism, sphingolipid metabolism, glycerophospholipid metabolism, diacylglycerol metabolism, amino acid metabolism, bile acid and taurine metabolism, taurine and hypotaurine metabolism. Moreover, DGs, GPs and SMs, and taurine itself may serve as active metabolites in facilitating various anti-hyperlipidemia signal pathways associated with taurine. This study provides new evidence for taurine to prevent hyperlipidemia.
BibTeX
@inproceedings{guo2024untargeted,
  author = {Xinzhe Guo and Tong Ou and Xinyu Yang and Qi Song and Lin Zhu and Shengquan Mi and Jing Zhang and Yanzhen Zhang and Wen Chen and Junxia Guo},
  title = {{Untargeted metabolomics based on ultra-high performance liquid chromatography-mass spectrometry/MS reveals the lipid-lowering mechanism of taurine in hyperlipidemia mice}},
  booktitle = {Frontiers in Nutrition},
  year = {2024},
  doi = {10.3389/fnut.2024.1367589},
}
Figure